BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-12 out of 12 found
  Current Search:  eligard: 12     

HTML
100%
MediGene to Present at the Piper Jaffray Conference in London
Internet live webcast available at MARTINSRIED/MUNICH, Germany, June 20, 2008.

The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) will give a presentation at the Piper Jaffray Conference in London.

The speech will be made...

Pharma Live:  Jun 20 2008 12:33PM
Matching: eligard
Find similar documents
HTML
100%
Allergan buys QLT's acne drug
Under the terms of the agreement, QLT will receive a one-time cash payment of approximately $150 million upon closing, which is expected to occur in the third quarter of 2008.

The transaction has been approved by the board of directors of...

Pharmaceutical Business Review:  Jun 11 2008 4:40AM
Matching: eligard
Find similar documents
HTML
100%
Research and Markets: QLT Inc: Premium Company Profile - Available Now
DUBLIN, Ireland-- (BUSINESS WIRE) -- Research and Markets (http://www.researchandmarkets.com/reports/c94190) has announced the addition of 'QLT Inc: Premium Company Profile' to their offering.

QLT was originally focused on discovering,...

SmartBrief:  Jun 10 2008 10:48AM
Matching: eligard
Find similar documents
HTML
100%
QLT sells acne medication rights to Allergan
Vancouver pharmaceutical company QLT Inc.

has taken a major step in its planned downsizing with the sale of a key drug for $150-million (U.S.) in cash.

QLT said yesterday that it has sold worldwide rights to its acne medication Aczone to...

Report On Business:  Jun 10 2008 8:59AM
Matching: eligard
Find similar documents
HTML
100%
QLT to Sell Acne Vulgaris Treatment to Allergan for $150M
GEN News Highlights GEN News Highlights QLTis transfering rights covering an acne vulgaris treatment to a subsidiary of Allergan for roughly $150 million.

Aczone is a topical medicine approved in the U.S.

and Canada.

The divestment of...

Genetic Engineering News:  Jun 10 2008 5:10AM
Matching: eligard
Find similar documents
HTML
100%
Research and Markets: QLT Inc: Premium Company Profile Available Now
Dublin - Research and Markets (http://www.researchandmarkets.com/reports/c94192) has announced the addition of 'QLT Inc: Premium Company Profile' to their offering QLT was originally focused on discovering, developing and commercializing...
Calibre Macro World:  Jun 9 2008 3:59PM
Matching: eligard
Find similar documents
HTML
100%
Research and Markets: QLT Inc: Premium Company Profile - Available Now
- Research and Markets (http://www.researchandmarkets.com/reports/c94190) has announced the addition of 'QLT Inc: Premium Company Profile' to their offering.

QLT was originally focused on discovering, developing and commercializing...

Pharma Live:  Jun 9 2008 2:33PM
Matching: eligard
Find similar documents
HTML
100%
QLT announces positive Health Canada decision on Aczone(R)
VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc.

announced today that Health Canada has completed its review of QLT USA, Inc.'s labeling supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate dehydrogenase (G6PD)...

SmartBrief:  Jun 9 2008 2:12AM
Matching: eligard
Find similar documents
HTML
100%
QLT announces positive Health Canada decision on Aczone(R)
VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc.

(NASDAQ: QLTI; TSX: QLT) announced today that Health Canada has completed its review of QLT USA, Inc.'s labeling supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate...

Rehab Manegement:  Jun 8 2008 5:26PM
Matching: eligard
Find similar documents
HTML
100%
QLT announces positive Health Canada decision on Aczone(R)
VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc.

announced today that Health Canada has completed its review of QLT USA, Inc.'s labeling supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate dehydrogenase (G6PD)...

KOTA Territory News:  Jun 7 2008 8:27AM
Matching: eligard
Find similar documents
HTML
100%
Arab investor in talks with MediGene: sources
FRANKFURT (Reuters) - An Arabic investor is in talks with MediGene, with options including taking a stake in the German biotech company, sources familiar with the matter said on Monday.

'There is a major interest,' one source told Reuters....

Clinical Lab Products:  Jun 3 2008 10:42PM
Matching: eligard
Find similar documents
HTML
100%
European Regulatory Authority (EMEA) Recommends Granting of Marketing Authorization for MediGene's Drug Oracea
A new era for MediGene: first drug to be marketed by the company itself MARTINSRIED/MUNICH, Germany, 25.

April 2008.

MediGene AG (Frankfurt, Prime Standard: MDG) announced that the European Medicines Agency (EMEA) Committee for Medicinal...

Pharma Live:  Apr 25 2008 1:13PM
Matching: eligard
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.